Breakthroughs in SARS-CoV-2-monoclonal antibodies development

In December 2019, cases of unknown pneumonia-like disease connected to food markets were reported in China. The causative agent was identified as a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and the which spread all over world, named COVID-19. This pandemic has negatively affected quality life economy worldwide, thus motivating thoughtful search for treatment prevention strategies. Efforts have been made drug repositioning vaccine development well monoclonal antibodies. Monoclonal antibodies provide long-lasting protective immunity against pathogens, at forefront line therapy some viral diseases. study aimed review advances SARS-CoV-2 (mAbs) development. Most developed including; B38, CR3022, 47D11, H4, targeted spike protein virus prevent its interaction with host cell ACE-2 receptor. However, others such Tocilizumab inflammation caused by cytokine storm.